Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Ovarian Cancer
What is your management of a stage 1A infiltrative subtype of mucinous ovarian carcinoma?
Appendix looks normal intraoperatively.
Related Questions
Would you recommend SBRT in the adjuvant settings for a solitary metastasis focus in the abdominal wall resected to R1 in a young and healthy patient with clear cell ovarian cancer?
What factors do you consider when deciding between 3 versus 4 cycles of BEP for ovarian germ cell tumors?
What platform do you use for HRD testing of ovarian cancers and why?
How should PARP inhibitors be incorporated into clinical practice in later line/maintenance of platinum-sensitive ovarian cancer for PARP inhibitor-naïve patients?
What outcome data do you view as most impactful to make treatment decisions regarding the use of PARP inhibitors in later line or recurrent ovarian cancer?
What toxicities related to mirvetuximab have you seen in your patients and how have you managed them?
Would you prescribe vaginal estrogen cream for vaginal dryness to a patient in her 40s with a history of stage IA granulosa cell tumor?
What hormonal therapy, if any, would you offer for adjuvant treatment of stage IC ER-/PR+ low grade serous ovarian cancer?
How do you counsel patients with homologous recombination repair proficient tumors already on niraparib maintenance therapy, prior to the FDA restriction?
What is your adjuvant treatment approach to patients with stage IC1 clear cell carcinoma of the ovary (intraoperative rupture)?